The trusted source for
healthcare information and
IDSA urges increased antibiotic development
To avert a looming public health crisis with a unique set of underlying causes, Congress and the administration, including federal public health agencies, must act quickly to reinvigorate pharmaceutical investment in antibiotic research and development (R&D). Otherwise, doctors won’t have drugs to protect Americans against antibiotic-resistant infections — a rapidly growing and often deadly problem. That is the key message of a recent report by the Infectious Diseases Society of America (IDSA). The IDSA recently presented its findings and recommendations to Congress and federal policy-makers.
While the number of drug-resistant infections continues to rise, the number of new antibiotics in the pipeline to treat these infections is drastically declining. Major pharmaceutical companies have abandoned or drastically cut back their antibiotic development efforts because of the unique challenges to making antibiotics profitable.
For example, antibiotics produce a weak return on investment for manufacturers because they work so well and so fast. Highlights of proposed policy and administrative actions in the report include the following:
Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates A Public Health Crisis Brews is available on the IDSA web site: www.idsociety.org.